** Shares of GH Research GHRS.O down 20.5% to $14.30 on Tues as co seeks equity to fund development of its treatments for depression
** GHRS shares surged 70% to close at $17.99 on Mon after co said its depression therapy, GH001, met main goals of mid-stage study
** After the bell Mon, Ireland-based biotech commenced $150 mln stock offering
** It plans to use net offering proceeds to invest in research, clinical and technical development of current and/or additional product candidates, according to the SEC filing
** Cantor, Stifel and RBC acting as jt bookrunners for the offering
** With ~52 mln shares outstanding, co has current market cap of roughly $760 mln
** Stock ended 2024 at $7
** All 5 analysts covering GHRS are bullish with median PT of $37, LSEG data shows
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.